Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 21k
1 August 2018
Answer given by President Juncker on behalf of the European Commission
Question reference: E-002776/2018

The Commission did not draw up an assessment of the impact of the withdrawal of the United Kingdom from the European Union in the area of medicines and healthcare products. The Commission would like to recall that the decision of the United Kingdom to withdraw from the Union was a unilateral decision of the United Kingdom. The Commission regrets, but respects, this decision. The Commission, the European Medicines Agency and EU 27 national competent authorities are taking all necessary measures to ensure preparedness of the European Union with regard to medicines and healthcare products. In particular, Commission services have published ‘preparedness notices’ to stakeholders as regards medicinal products (jointly with the European Medicines Agency) and medical devices. More information is available on the respective website of the Commission services(1) and of the European Medicines Agency(2).


Last updated: 2 August 2018Legal notice